Liu Geng Tao, Li Yan, Wei Huai Ling, Zhang Hui, Xu Ji Yan, Yu Ling Hong
Department of Pharmacology, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Liver Int. 2005 Aug;25(4):872-9. doi: 10.1111/j.1478-3231.2005.01103.x.
Bicyclol is a novel synthetic drug for the treatment of chronic viral hepatitis in China. This paper reports the protective action of bicyclol against experimental liver injury in mice and its mechanism of action. Oral administration of bicyclol markedly reduced the elevated serum transaminases (alanine aminotransferase (ALT) and aspartate aminotransferase (AST)) and the hepatic morphologic changes induced by CCl(4) in mice. Mechanistic studies demonstrated that bicyclol significantly inhibited CCl(4)-induced lipid peroxidation of liver microsomes and (14)CCl(4) covalent binding to microsomal lipids and proteins in vitro, and decreased the level of the trichloromethyl free radical (*CCl(3)) generated from CCl(4) metabolism by NADPH-reduced liver microsomes. On the other hand, bicyclol neither directly inhibited the activity of ALT or AST in vitro nor affected hepatic ALT protein content in mice. These results suggest that bicyclol has remarkable hepatoprotective effects and its mechanism of action may be related to a decrease in free radical-induced damage to hepatocytes.
双环醇是中国一种用于治疗慢性病毒性肝炎的新型合成药物。本文报道了双环醇对小鼠实验性肝损伤的保护作用及其作用机制。口服双环醇可显著降低四氯化碳诱导的小鼠血清转氨酶(丙氨酸转氨酶(ALT)和天冬氨酸转氨酶(AST))升高以及肝脏形态学变化。机制研究表明,双环醇在体外可显著抑制四氯化碳诱导的肝微粒体脂质过氧化以及(14)CCl4与微粒体脂质和蛋白质的共价结合,并降低由NADPH还原的肝微粒体对四氯化碳代谢产生的三氯甲基自由基(*CCl3)水平。另一方面,双环醇在体外既不直接抑制ALT或AST的活性,也不影响小鼠肝脏ALT蛋白含量。这些结果表明,双环醇具有显著的肝保护作用,其作用机制可能与减少自由基对肝细胞的损伤有关。